ArticleInternational journal of hematology2019
A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.
Tadashi Kumamoto et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it